143 related articles for article (PubMed ID: 1655465)
1. Target cell-induced T cell activation with bi- and trispecific antibody fragments.
Jung G; Freimann U; Von Marschall Z; Reisfeld RA; Wilmanns W
Eur J Immunol; 1991 Oct; 21(10):2431-5. PubMed ID: 1655465
[TBL] [Abstract][Full Text] [Related]
2. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
4. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
5. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
6. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
7. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
8. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
9. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
10. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
[TBL] [Abstract][Full Text] [Related]
11. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
12. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
13. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
14. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
15. Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies.
Bjorndahl JM; Sung SS; Hansen JA; Fu SM
Eur J Immunol; 1989 May; 19(5):881-7. PubMed ID: 2544432
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
17. T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibody.
Roosnek E; Tunnacliffe A; Lanzavecchia A
Eur J Immunol; 1990 Jun; 20(6):1393-6. PubMed ID: 2142461
[TBL] [Abstract][Full Text] [Related]
18. Temperature requirements and kinetics of T cell signaling. Velocity of triggering correlates with functional effects of anti-CD3 mAb.
Abdi K; Reed ML; Mentzer SJ; Herrmann SH
J Immunol; 1989 May; 142(9):2971-80. PubMed ID: 2468707
[TBL] [Abstract][Full Text] [Related]
19. Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R- memory T lymphocytes.
Damle NK; Doyle LV
J Immunol; 1989 Sep; 143(6):1761-7. PubMed ID: 2570801
[TBL] [Abstract][Full Text] [Related]
20. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
